SCHEMBL1242473

SCHEMBL1242473

OC(c1ccccn1)(c1ccccn1)C(c1cccc(Cl)c1)N1CC(F)(F)C1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM4 Q14833 1/20 0.36
HDAC6 Q9UBN7 1/20 0.36
OPRM1 P35372 1/20 0.35
OPRD1 P41143 1/20 0.35
OPRK1 P41145 1/20 0.35
OPRL1 P41146 1/20 0.35
CACNA2D1 P54289 2/20 0.35
CACNA1B Q00975 2/20 0.35
CACNB1 Q02641 2/20 0.35
CACNA1C Q13936 2/20 0.35
L3MBTL1 Q9Y468 2/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
KDR P35968 1/20 0.34
ALDH1A1 P00352 1/20 0.34
CACNA1G O43497 1/20 0.33
NFE2L2 Q16236 1/20 0.32
MAPT P10636 2/20 0.32
ATM Q13315 1/20 0.32
KCNQ3 O43525 1/20 0.32
KCNQ2 O43526 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9903755 0.80 KCNA5 (0.52)
SCHEMBL1243096 0.70 CYP19A1 (0.43)
SCHEMBL1242799 0.66 KCNA5 (0.70)
SCHEMBL1243557 0.64 KCNA5 (0.64) L3MBTL1SMN1; SMN2
SCHEMBL1242865 0.64 KCNA5 (0.49)
SCHEMBL1243278 0.64 KCNA5 (0.73)
SCHEMBL22319803 0.62 SMN1; SMN2 (0.56) GRM4HDAC6L3MBTL1SMN1; SMN2NFE2L2
SCHEMBL1240383 0.62 KCNA5 (0.75) ALDH1A1
SCHEMBL16132316 0.61 SMN1; SMN2 (0.59) OPRK1L3MBTL1SMN1; SMN2ALDH1A1
SCHEMBL1241019 0.61 KCNA5 (0.58)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7879839-B2 For treatment and prevention of cardiac arrhythmias; (+-)-2-Morpholin-4-yl-2-phenyl-1,1-dipyridin-3-yl-ethanol; (+-)-2-[(2-methoxyethyl)(methyl)amino]-2-phenyl-1,1-dipyridin-3-ylethanol MERCK SHARP & DOHME CORP. (US) 2011-02-01 US disclosed
US-20080090794-A1 Potassium Channel Inhibitors MERCK SHARP & DOHME LLC 2008-04-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080090794-A1 Potassium Channel Inhibitors KCNJ2, KCNQ2, KCNH2 GRM4 2449/4885HDAC6 1011/4885OPRM1 3425/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.